New Ovarian Cancer Treatment Approved, Promising Longer Life
WHO:
The Guardian - NHS England approved the new treatment.
The Guardian - Prof Ruth Plummer is NHS England’s national clinical lead for cancer drugs.
The Guardian - Rachel Downing is the head of policy and external affairs at Target Ovarian Cancer.
The Guardian - Victoria Clare is the chief executive of the charity Ovacome.
The Guardian - Helen Knight is the director of medicines evaluation at Nice.
BBC - A representative from the medical community stated the benefits of the new drug.
WHAT:
The Guardian - The drug mirvetuximab soravtansine, also known as Elahere, is approved for patients with epithelial ovarian, peritoneal, or fallopian tube cancer that has become resistant to platinum-based chemotherapy.
The Guardian - The approval of mirvetuximab soravtansine is described as a major milestone for treatment by NHS England.
The Guardian - NHS England approved the drug mirvetuximab soravtansine for advanced ovarian cancer.
The Guardian - This is the first new drug for resistant ovarian cancer approved in over 20 years.
The Guardian - Up to 400 women a year in England could benefit from this treatment.
The Guardian - The treatment delayed cancer progression and prolonged survival by an average of four months compared to chemotherapy.
The Guardian - In more than a third of patients (37%), tumours shrank by at least 30%, compared to 16% with chemotherapy.
WHERE:
The Guardian - The treatment is approved for use in England.
The Guardian - A global clinical trial involved eight NHS hospitals.
WHEN:
The Guardian - The drug is administered by a drip once every three weeks.
WHY:
The Guardian - Patients with FRα cancers have had limited options when their tumors stop responding to standard chemotherapy, making this approval significant.
The Guardian - Patients with FRα cancers had limited options when their tumours stopped responding to standard chemotherapy.
The Guardian - The approval represents a significant breakthrough for hard-to-treat ovarian cancers.
HOW:
The Guardian - Mirvetuximab soravtansine combines a “homing” antibody that targets the FRα protein on cancer cells with a cancer-killing molecule that destroys the cell from within, offering a new treatment option.
The Guardian - Mirvetuximab soravtansine combines a “homing” antibody that targets the FRα protein on cancer cells with a cancer-killing molecule.
(UPDATED June 4, 2026 10:17 UTC)
The drug mirvetuximab soravtansine, also known as Elahere, has received approval for patients suffering from epithelial ovarian, peritoneal, or fallopian tube cancer that has become resistant to platinum-based chemotherapy. This approval is being hailed as a major milestone for treatment by NHS England, especially since patients with FRα cancers have faced limited options when their tumors stop responding to standard chemotherapy. Mirvetuximab soravtansine works by combining a “homing” antibody that targets the FRα protein on cancer cells with a cancer-killing molecule that destroys the cell from within, providing a promising new treatment avenue.
--
(UPDATED June 4, 2026 08:21 UTC)
NHS England has approved a groundbreaking new treatment for advanced ovarian cancer called mirvetuximab soravtansine, marking the first new drug for resistant ovarian cancer in over 20 years. This innovative treatment, which is administered by a drip once every three weeks, has shown promising results, delaying cancer progression and prolonging survival by an average of four months compared to traditional chemotherapy, with up to 400 women in England expected to benefit each year. The approval represents a significant breakthrough for patients with FRα cancers, who previously had limited options when their tumors stopped responding to standard treatments.